ADPR Therapeutic Agent for RNA and Herpes Virus Management
Solution Overview
Problem
Current treatments lack effective methods for managing or preventing RNA virus-related diseases, herpes virus-related diseases, Sirtuin 6 (Sirt6)-related diseases, Pax6-related diseases, and p53-related diseases.
Innovation Solution
Administration of 5′-adenosine diphosphate ribose (ADPR) or its pharmaceutically acceptable salts, solvates, hydrates, tautomers, stereoisomers, isotopologues, or polymorphs to patients at risk or with these diseases, to treat, manage, or prevent them.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If current treatments are used for RNA virus-related diseases, then existing therapeutic approaches are maintained, but effective management and prevention of these diseases is lacking
Solution Approach 1:
The patent applies ADPR as a universal therapeutic agent that can treat multiple types of diseases including RNA virus-related diseases, herpes virus-related diseases, Sirt6-related diseases, Pax6-related diseases, and p53-related diseases. This multi-functional approach resolves the contradiction by providing a single compound with broad therapeutic applicability across diverse disease categories.
2Adaptability or versatility
If ADPR is administered to treat multiple disease types, then therapeutic versatility is improved, but the mechanism of action across different disease targets must be validated
Solution Approach 1:
The patent utilizes ADPR's ability to interact with different molecular targets (Sirt6, Pax6, p53) by changing the biological parameter being modulated. ADPR acts as an inhibitor of Sirt6, while also potentially increasing the activity of Pax6 and p53, demonstrating parameter changes in molecular activity levels to achieve versatile therapeutic effects across different disease types.
Data Source
AI summary
The present invention is directed to methods for the use of 5′-adenosine diphosphate ribose (ADPR), and compositions thereof, for treating, managing, or preventing RNA virus-related diseases or conditions, herpes virus related diseases or conditions, Sirtuin 6 (Sirt6)-related diseases or conditions, Pax6 related diseases or conditions, and p53 related diseases or conditions.